LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival. This study suggests phenformin as a cancer metabolism-based therapeutic to selectively target LKB1-deficient tumors.

[1]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[2]  D. Smithers,et al.  Cancer Research , 1972, Nature.

[3]  T. Jacks,et al.  SnapShot: Lung Cancer Models , 2012, Cell.

[4]  E. White,et al.  Metabolic catastrophe as a means to cancer cell death , 2007, Journal of Cell Science.

[5]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[6]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[7]  R. Memmott,et al.  Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.

[8]  Leah E. Mechanic,et al.  Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer , 2011, Oncogene.

[9]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[10]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[11]  B. Viollet,et al.  Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. , 2010, Cell metabolism.

[12]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[13]  J. Nestler.  Metformin for the treatment of the polycystic ovary syndrome. , 2008, The New England journal of medicine.

[14]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[15]  Saroj Niraula,et al.  Metformin in cancer: translational challenges. , 2012, Journal of molecular endocrinology.

[16]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[17]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[18]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[19]  Kei Sakamoto,et al.  Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction , 2005, The EMBO journal.

[20]  D. Sabatini,et al.  Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson , 2012, Nature Medicine.

[21]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[22]  M. Pollak.  Metformin and Other Biguanides in Oncology: Advancing the Research Agenda , 2010, Cancer Prevention Research.

[23]  Xu Huang,et al.  Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. , 2008, The Biochemical journal.

[24]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[25]  A. Murphy,et al.  Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. , 2002, The Biochemical journal.

[26]  G. Taubes.  Cancer research. Cancer prevention with a diabetes pill? , 2012, Science.

[27]  M. Pollak,et al.  Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo , 2011, Oncogene.

[28]  M. Wilkerson,et al.  Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.

[29]  F. Ross,et al.  Use of Cells Expressing gamma Subunit Variants to Identify Diverse Mechanisms of AMPK Activation , 2010 .

[30]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[31]  Y. Ichinose,et al.  LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. , 2011, Japanese journal of clinical oncology.

[32]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[33]  B. Viollet,et al.  5′-AMP-Activated Protein Kinase (AMPK) Is Induced by Low-Oxygen and Glucose Deprivation Conditions Found in Solid-Tumor Microenvironments , 2006, Molecular and Cellular Biology.

[34]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[35]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[36]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.

[37]  M. Herlyn,et al.  Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. , 2012, Cancer cell.

[38]  C. Franceschi,et al.  Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2005, Experimental Gerontology.

[39]  S. Morrison,et al.  Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells , 2010, Nature.

[40]  Jiangbin Ye,et al.  The GCN2‐ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation , 2010, The EMBO journal.

[41]  Lewis C Cantley,et al.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Marroquin,et al.  Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.

[43]  Andrew L. Kung,et al.  Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination , 2003 .

[44]  F. Ross,et al.  Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation , 2010, Cell metabolism.

[45]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[46]  M. Pollak.  Investigating metformin for cancer prevention and treatment: the end of the beginning. , 2012, Cancer discovery.

[47]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[48]  Chin-Lee Wu,et al.  mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome , 2009, Proceedings of the National Academy of Sciences.

[49]  A. Thompson,et al.  Phenformin as prophylaxis and therapy in breast cancer xenografts , 2012, British Journal of Cancer.

[50]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[51]  D. Scheuner,et al.  Phosphorylation of eIF2α at Serine 51 Is an Important Determinant of Cell Survival and Adaptation to Glucose Deficiency , 2010, Molecular biology of the cell.

[52]  M. Meyerson,et al.  TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity , 2009, Oncogene.

[53]  J. Hirst,et al.  The production of reactive oxygen species by complex I. , 2008, Biochemical Society transactions.